The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Graf Finckenstein Friedrich since 2022.
This trader's CIK number is 1782981.
At the time of last reporting, Graf Finckenstein Friedrich was the Chief Medical Officer of Iovance Biotherapeutics, Inc.. (stock ticker symbol IOVA).
Also see all insider trading activities at Iovance Biotherapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | IOVA | 0 | $0 | 0 | $0 | 90,702 | $0 |
| 2024 | IOVA | 0 | $0 | 0 | $0 | 62,031 | $0 |
| 2023 | IOVA | 0 | $0 | 0 | $0 | 28,128 | $0 |
| 2022 | IOVA | 0 | $0 | 0 | $0 | 19,690 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-09-02 | IOVA | Option Ex | 12,697 | .00 | 0 |
| 2025-06-02 | IOVA | Option Ex | 12,695 | .00 | 0 |
| 2025-03-03 | IOVA | Option Ex | 62,497 | .00 | 0 |
| 2025-01-14 | IOVA | Option Ex | 2,813 | .00 | 0 |
| 2024-12-02 | IOVA | Option Ex | 3,906 | .00 | 0 |
| 2024-10-14 | IOVA | Option Ex | 2,813 | .00 | 0 |
| 2024-09-03 | IOVA | Option Ex | 27,345 | .00 | 0 |
| 2024-07-15 | IOVA | Option Ex | 2,813 | .00 | 0 |
| 2024-06-03 | IOVA | Option Ex | 3,906 | .00 | 0 |
| 2024-04-15 | IOVA | Option Ex | 2,812 | .00 | 0 |
| 2024-03-04 | IOVA | Option Ex | 15,623 | .00 | 0 |
| 2024-01-16 | IOVA | Option Ex | 2,813 | .00 | 0 |
| 2023-10-16 | IOVA | Option Ex | 2,813 | .00 | 0 |
| 2023-07-14 | IOVA | Option Ex | 2,813 | .00 | 0 |
| 2023-04-14 | IOVA | Option Ex | 2,812 | .00 | 0 |
| 2023-01-03 | IOVA | Option Ex | 19,690 | .00 | 0 |
| 2022-06-14 | IOVA | Option Ex | 19,690 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Graf Finckenstein Friedrich (Chief Medical Officer of Iovance Biotherapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.